Cancer of the Urinary and Reproductive Tracts

  • Inka Brockhausen
  • William Kuhns
Part of the Medical Intelligence Unit book series (MIU.LANDES)


An association of ovarian cancer with ABO blood groups has been described in large population samples.1 This was confirmed in a recent study of 1261 women with ovarian cancer. Comparison of blood group A patients with a large normal cohort confirmed earlier findings which stated that the cancer risk in the former group was 1.2 with 1 considered as the risk factor in normals.2 A possible explanation is that many tumors which may express Forssman A-like antigen could be eliminated by naturally occurring anti-A in non-A persons; this form of immune surveillance would be absent in A individuals.


Ovarian Cancer Blood Group Endometrial Adenocarcinoma BeWo Cell Lewis Antigen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Mourant A, Kopec A, Domaniewska-Sobczak K. Blood Groups and Diseases. Oxford University Press, Oxford, 1978: 13–15.Google Scholar
  2. 2.
    Henderson J, Seagroatt V, Goldacre M. Ovarian cancer and ABO blood groups. J Epidemiol Commun Health 1993; 47: 287–289.CrossRefGoogle Scholar
  3. 3.
    Podolsky DK, MM, Isselbacher KJ et al. A cancer-associated galactosyltransferase isoen- zyme. New Eng J Med 1978; 299: 703–705.PubMedCrossRefGoogle Scholar
  4. 4.
    Chatterjee SK, Battacharya M, Barlow JJ. Biochemical and immunologic characterization of galactosyltransferase purified from the ascites of ovarian cancer patients. J Natl Cancer Inst 1985; 75: 237–248.PubMedGoogle Scholar
  5. 5.
    Uemura M, Sakaguchi T, Uejima T et al. Mouse monoclonal antibodies which recognize a human (13l-4)galactosyltransferase associated with tumor in body fluids. Cancer Res 1992; 52: 6153–6157.PubMedGoogle Scholar
  6. 6.
    Uejima T, Uemura M, Nozawa S et al. Complementary DNA cloning for galactosyltransferase associated with tumor and determination of antigenic epitopes recognized by specific monoclonal antibodies. Cancer Res 1992; 52: 6158–6163.PubMedGoogle Scholar
  7. 7.
    Turner GA, Goodarzi MT, Thompson S. Glycosylation of alpha-l-proteinase inhibitor and haptoglobin in ovarian cancer: evidence for two different mechanisms. Glycoconj J 1995; 12: 211–218.PubMedCrossRefGoogle Scholar
  8. 8.
    Thompson S, Cantwell BMJ, Matta KL et al. Parallel changes in the blood levels of abnormally-fucosylated haptoglobin and alpha 1,3 fucosyltransferase in relationship to tumour burden: more evidence for a disturbance of fucose metabolism in cancer. Cancer Letters 1992; 65: 115–121.PubMedCrossRefGoogle Scholar
  9. 9.
    Chandreskaran EV, Jain RK, Matta KL. Ovarian cancer a1,3-L-fucosyltransferase. J Biol Chem 1992; 267: 23806–23814.Google Scholar
  10. 10.
    Devine PL, McGuckin MA, Quin RJ et al. Serum markers CASA and CA 15–3 in ovarian cancer; all MUC1 assays are not the same. Tumor Biol 1994; 15: 337–344.CrossRefGoogle Scholar
  11. 11.
    Tashiro Y, Yonezawa S, Kim YS et al. Immunohistochemical study of mucin carbohydrates and core proteins in human ovarian tumors. Hum Pathol 1994; 25: 364–372.PubMedCrossRefGoogle Scholar
  12. 12.
    Ioannides C, Fisk B, Jerome K et al. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J Immunol 1993; 151: 3693–3703.PubMedGoogle Scholar
  13. 13.
    Inoue M, Ogawa H, Tanizawa O et al. Immunodetection of sialyl-Tn antigen in normal, hyperplastic and cancerous tissues of the uterine endometrium. Virchows Archiv 1991; 48: 157–162.Google Scholar
  14. 14.
    Kobayashi H, Terao T, Kawashima Y. Serum sialyl Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer. J Clin Oncol 1992; 10: 95–101.PubMedGoogle Scholar
  15. 15.
    Ravn V, Teglbjaerg CS, Mandel U et al. The distribution of type 1 chain ABH and related histo-blood group antigens in normal cycling human endometrium. Int J Gynec Path 1993; 12: 70–79.CrossRefGoogle Scholar
  16. 16.
    Kubushiro K, Tsukazaki K, Sakuma Y et al. Enzymatic basis for the accumulation of Lewis(b) antigen in uterine endometrial cancer. Jap J Cancer Res 1995; 86: 361–367.CrossRefGoogle Scholar
  17. 17.
    Shiozawa T, Tsukuhara Y, Nakayama J et al. Immunohistochemical localization of blood group substances in normal and neo-plastic endometrial tissues-with special reference to type 1 core chain expression. Gynec Obstet Invest 1991; 32: 185–188.PubMedCrossRefGoogle Scholar
  18. 18.
    Memon RS, Yonezawa S, Hasui K et al. Expression of blood group antigens and lectin binding in adenocarcinomas of the endometrium. Acta Pathol Jpn 1990; 40: 509–516.PubMedGoogle Scholar
  19. 19.
    Amano J, Nishimura R, Mochizuki M et al. Comparative study of the mucin-type sugar chains of human chorionic gonadotropin present in the urine of patients with trophoblastic diseases and healthy pregnant women. J Biol Chem 1988; 263: 1157–1165.PubMedGoogle Scholar
  20. 20.
    Cole LA. The 0-linked oligosaccharide structures are striking different on pregnancy and choriocarcinoma hCG. J Clin Endocrin Metab 1987; 65: 811–813.CrossRefGoogle Scholar
  21. 21.
    Hard K, Damm JB, Spruijt MP et al. The carbohydrate chains of the beta subunit of human chorionic gonadotropin produced by the choriocarcinoma cell line BeWo. Novel 0-linked and novel bisecting-G1cNAc-containing N-linked carbohydrates. Eur J Biochem 1992; 205: 785–798.PubMedCrossRefGoogle Scholar
  22. 22.
    Mizuochi T, Nishimura R, Derappe C et al. Structures of the Asparagine-linked sugar chains of human chorionic gonadotropin produced in choriocarcinoma. J Biol Chem 1983; 258: 14126–14129.PubMedGoogle Scholar
  23. 23.
    Nishimura R, Endo Y, Tanabe K et al. The biochemical properties of urinary human chorionic gonadotropin from the patients with trophoblastic diseases. J Endocrin Invest 1981; 4: 349–358.Google Scholar
  24. 24.
    Holland JF, Frei E, Bast RC Jr et al. In: Lea and Febiger, Cancer Medicine 3rd Ed Vol 1. Philadelphia: 1993; 132–134.Google Scholar
  25. 25.
    Holland JF, Frei E, Bast RC Jr et al. In: Lea and Febiger. Cancer Medicine 3rd Ed Vol 1. Philadelphia: 1993; 324.Google Scholar
  26. 26.
    Lundgren R, Heim S, Mandahl M et al. Chromosome abnormalities are associated with unfavorable outcome in prostate cancer patients. J Urol 1992; 147: 784–878.PubMedGoogle Scholar
  27. 27.
    Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991; 145: 907–923.PubMedGoogle Scholar
  28. 28.
    Jorgensen T, Berner A, Kaalhus A et al. Upregulation of the oligosaccharide sialyl Lewis’: new prognostic parameter in metastatic prostate cancer. Cancer Res 1995; 55: 1817–1819.PubMedGoogle Scholar
  29. 29.
    Mârtensson S, Bigler SA, Brown M et al. Sialys-Lewis“ and related carbohydrate antigens in the prostate. Hum Pathol 1995; 26: 735–739.PubMedCrossRefGoogle Scholar
  30. 30.
    Kadomatsu K, Anzano M, Slayter M et al. Expression of sulfated glycoprotein-2 is associated with carcinogenesis induced by N-nitroso-N-methylurea in rat prostate and seminal vesicle. Cancer Res 1993; 53: 1480–1483.PubMedGoogle Scholar
  31. 31.
    orntoft TF. Carbohydrate changes in bladder carcinoma. APMIS 1992; 100 Suppl 27: 181–187.Google Scholar
  32. 32.
    Orntoft TF, Wolf H, Watkins W. Activity of the human blood group ABO, Se, H, Le, and X gene-encoded glycosyltransferases in normal and malignant bladder urothelium. Cancer Res 1988; 48: 4427–4433.PubMedGoogle Scholar
  33. 33.
    Srinivas V, Khan A, Hoisington S et al. Relationship of blood groups and bladder cancer. J Urol 1986; 135: 50–52.PubMedGoogle Scholar
  34. 34.
    Fukushi Y, Orikasa S, Shepard T et al. Changes of Le“ and dimeric Le’ haptens and their sialylated antigens during development of human kidney and kidney tumors. J Urol 1986; 126: 1048–1056.Google Scholar
  35. 35.
    Meldgaard P, Holmes EH, Bennett EP et al. Blood group ABO-related glycosylation of urothelial cell lines: Immunocytological, enzymatic, and genetic characterization. Cancer Res 1994; 54: 2440–2447.PubMedGoogle Scholar
  36. 36.
    Langkilde NC, Wolf H, Clausen H et al. Nuclear volume and expression of T-antigen, Sialosyl-Tn-antigen and Tn-antigen in carcinoma of the human bladder. Cancer 1992; 69: 219–227.PubMedCrossRefGoogle Scholar
  37. 37.
    Coon JS, Weinstein RS. Blood group antigens in tumor cell membranes. Bio-membranes 1983; 11: 173–205.Google Scholar
  38. 38.
    Plotkin GM, Wides RJ, Gilbert SL et al. Galactosyl transferase activity in human transitional cell carcinoma lines and in benign and neoplastic human bladder epithelium. Cancer Res 1979; 39: 3856–3860.PubMedGoogle Scholar
  39. 39.
    Plotkin GM, Gilbert SL, Wides RJ et al. Galactosyltransferase activity in rat bladder transitional cell carcinoma lines and in exfoliated cells in urine during carcinogenesis and reversible hyperplasia. Cancer Biochemistry Biophysics 1980; 4: 251–256.PubMedGoogle Scholar
  40. 40.
    Gmeiner B, Wolf B. Comparison of cell-associated and soluble galactosyltransferase isoenzymes from a human bladder transitional cell carcinoma line. Cancer Res 1987; 47: 2311–2316.PubMedGoogle Scholar
  41. 41.
    Bergeron A, LaRue H, Fradet Y. Identification of a superficial bladder tumor-associated glycoform of the carcinoembryonic antigen by monoclonal antibody 19A211. Cancer Res 1996; 56: 908–915.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1997

Authors and Affiliations

  • Inka Brockhausen
    • 1
  • William Kuhns
    • 1
  1. 1.Department of Biochemistry, Research Institute, Hospital for Sick ChildrenUniversity of TorontoTorontoCanada

Personalised recommendations